Open Orphan Plc #ORPH announces the launch of HVIVO COVID Clear Test, the Company's antibody testing service, following the successful completion of installation, testing and training...
Samples will be tested in the Company's London laboratory with results returned within 48 hours. The Company is hosting a press event at its clinic in East London at 11 am today details of which can be found at: We are very excited to be offering this service and I am confident our work will help large companies and...
RNS Number: 1064 O Euronext Dublin 29 May 2020. 44,496,864 Ordinary Shares GBP 0.001 GB00B9275X97. The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Euronext UK Markets, referred to respectively as the Amsterdam, Brussels, Dublin, Lisbon, Paris and London markets, as...
Open Orphan #ORPH successfully completes oversubscribed fundraising of £12m net, through placing of 109,549,098 shares, PrimaryBid offer of 4,545,454 shares & 727,272 new share subscription, all at 11p
RNS Number: 7692 N Open Orphan PLC 22 May 2020 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH...
Open Orphan Plc (ORPH.L) Announced its intention to raise up to £12.00 million (net of expenses) via a placing of new Ordinary Shares to institutional and other investors, subscription of new Ordinary Shares to certain investors and an offer subscription for new Ordinary Shares by PrimaryBid, all at a price of 11.00p per new Ordinary Share. The company also announced a conditional offer for subscription via PrimaryBid of new ordinary shares at an issue price of 11.00p per New Ordinary Share, a premium of 3.8% to the closing price of 10.6p per Ordinary Share on 7 May 2020 being the date immediately before the announcement of the Quotient partnership on 11 May 2020. #ORPH
Open Orphan #ORPH announces a proposed fundraising to raise up to £12m via placing & PrimaryBid offer. The funds will be used to maximise available Covid_19 opportunities, ramp up testing & expand lab testing services to 3rd party pharma & biotechs
Open Orphan Plc, a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce a conditional offer for subscription via PrimaryBid of new ordinary shares at an issue price of 11 pence per New Ordinary...
RNS Number: 7391 N Open Orphan PLC 22 May 2020 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE...
Open Orphan Plc #ORPH Announced the increase in the company's share price and media comment regarding its collaboration with Quotient Limited. Furthermore, it also notes the substantial increase in interest in antibody testing for Covid-19 following recent announcements by the UK Government. The company confirms that the MosaiQ COVID-19 Antibody Microarray machine is on site at hVivo's laboratory in East London and is undergoing testing. It is expected to be fully operational within two weeks following which it will have capability to undertake up to 3,000 tests a day, in line with expected performance as stated by Quotient Limited. The Company intends to enter into discussions with channel partners to secure testing volumes with pricing to be determined as part of these negotiations.
Furthermore, it also notes the substantial increase in interest in antibody testing for Covid-19 following recent announcements by the UK Government.. The Company confirms that the MosaiQ COVID-19 Antibody Microarray machine is on site at hVivo's laboratory in East London and is undergoing testing. £70 for home testing kits and upwards towards c.
#ORPH presentation at ShareSoc webinar 11th May 2020. Company overview, strategy & plans for Imutex.
Open Orphan Plc (ORPH.L) Announced that it has appointed finnCap Ltd as its joint broker with immediate effect. Separately, the company announced that Quotient has entered into an exclusive contract with hVIVO to support COVID-19 antibody testing in the UK. The MosaiQTM by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). The MosaiQ COVID-19 Antibody Microarray was CE marked (certified to meet EU requirements) as of 01 May 2020 based on testing that demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies). The test is designed as a serological disease screen specific to COVID-19. It detects the IgG and IgM antibodies that humans develop when infected by SARS-CoV-2. #ORPH
#ORPH Open Orphan & Quotient Limited enter into exclusive contract with hVIVO to support COVID19 antibody testing in the UK. Franz Walt, CEO of Quotient, said: “This collaboration marks a major milestone for our company, and we are proud to collaborate with an industry leader like hVIVO...."
Open Orphan plc
ORPH.L
Open Orphan plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    549.04M

Featured Media

Company Profile

Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise. Open Orphan is listed on both the London and Dublin stock exchanges.

Classification

Market Indices-
Watchlist